Published on : Jun 03, 2016
ALBANY, New York, June 03, 2016: The report studies the global respiratory syncytial virus market in detail and presents projections as to how it is expected to shape up in the coming years. The report, titled ‘Respiratory Syncytial Virus Infections- Market Insights, Epidemiology and Market Forecast-2020,’ is prepared by experienced analysts. It predicts that the global market for preventive therapies against respiratory syncytial virus infections will rise from a valuation of US$148.9 mn to US$777.49 mn over the report’s 2010-2020 forecast period.
The human respiratory syncytial virus (RSV) is a type of virus formed by multiple fusions of single cells. It can cause infections of the respiratory tract. Infants with congenital problems related to the cardiac system or the trachea have a heightened risk of contracting a respiratory syncytial virus infection. Common colds are a common symptom of respiratory syncytial virus infection; the infection can also be asymptomatic. While there are no major complications that can arise from respiratory syncytial virus infections, severe attacks during childhood can cause asthma or bronchiolitis and increase the chances of further attacks.
The report begins by providing a complete medical background of respiratory syncytial virus infections. Symptoms, etiology, diagnosis methodologies, and treatment procedures are listed in the report to brief the readers about the pathophysiological background of RSV infections. The major treatment for respiratory syncytial infections consists of oxygen and fluid supply to ease the natural action against the virus. However, palivizumab (marketed as Synagis by MedImmune) has emerged as a potential treatment for respiratory syncytial virus infection. Palivizumab attacks the protein responsible for the fusion of RSV, rendering it incapable of attacking human cells.
Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=720126
Europe, the U.S., and the Middle East are the prime regional segments of the global RSV infection market studied in the report. A demographic breakdown of patients of RSV infections in the U.S. and Europe is given in the report. Along with this, the recorded sales and sales projections of therapeutic molecules sold in the RSV infection therapeutics market are given in the report.
Within Europe, major markets such as Germany, France, Spain, the U.K., and Italy are examined. These are the prime developed countries in Europe and contain some of the most advanced and widespread national healthcare systems in Europe. Among Middle Eastern countries, the UAE, Saudi Arabia, Egypt, Turkey, Kuwait, Qatar, Jordan, Oman, Tunisia, and Lebanon are the countries for which data regarding respiratory syncytial virus infections is provided in the report.
Regional data about the respiratory syncytial virus market is given for a forecast period from 2010 to 2020, including data regarding the market’s development from 2010 till the present time and data about the projected growth of the market till 2020.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org